Cryoablation in Combination (or Not) With Pembrolizumab and Pemetrexed-carboplatin in 1st-line Treatment for Patients With Metastatic Lung Adenocarcinoma

This study is testing whether adding cryoablation — a procedure that uses extreme cold to destroy a tumor — to standard first-line immunotherapy and chemotherapy improves treatment outcomes for people with metastatic lung adenocarcinoma (a subtype of lung cancer that has spread). Researchers believe destroying one tumor with cold may help the immune system attack other tumors elsewhere in the body. **You may be eligible if...** - You are 18 years or older - You have confirmed metastatic lung adenocarcinoma (not squamous cell or other types) - You are receiving pembrolizumab combined with pemetrexed and carboplatin as first-line treatment - You have at least two measurable tumors: one suitable for repeated measurement and one suitable for cryoablation (15–40 mm in the lung, kidney, adrenal gland, soft tissue, or bone) - You are in good enough condition (performance status of 2 or less) **You may NOT be eligible if...** - You have squamous cell lung cancer - You have already received systemic treatment for advanced lung cancer - You have taken immune-suppressing drugs (including oral steroids) in the 3 weeks before starting - The tumors suitable for cryoablation are in the liver or sclerotic bone - You are pregnant Talk to your doctor to see if this trial is right for you.